Cancer immunotherapy: moving beyond current vaccines

By S. Rosenberg, Jie Yang, N. Restifo. Nature Medicine, 2004

3,071 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/6c000aa78abfa8c2973c0ab614381a40b42d805d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Molecular Biology

In Oncology

Citations in the corpus

Oral squamous cell carcinoma: review of prognostic and predictive factors. (2006, background): “These facts highlight the importance of immune response in tumor control and the potential value of cancer immunotherapy.(22,23) Some specific symptoms, such as odynophagia, oral abnormal hemorrhage, and weight loss, also have been correlated with shorter survival.”
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response (2014, neutral): “Melanoma 20 7 (35) 4 (20) 11 (55) 28, 10, 8, 6þ, 5, 3, 3 58þ, 54þ, 40þ, 24”
Adoptive cell transfer: a clinical path to effective cancer immunotherapy (2008, background): “Currently, only rare and highly sporadic regressions of solid cancers have been achieved using active immunizatio”
Cancer immunotherapy: the beginning of the end of cancer? (2016, background): “the mechanisms of immunization, and particularly of the role of dendritic cells (DCs), has led to a series of failures of therapeutic cancer vaccines in initial randomized trials [5, 8].”
Vaccine Adjuvants: Putting Innate Immunity to Work (2010, background): “…be necessary to generate potent and perhaps multifunctional T cell responses in patients who respond poorly to the relevant tumor or viral Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 493 antigens as a result of multiple layers of immune regulation (Gale and Foy, 2005; Rosenberg et al., 2004).”
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma (2010, background): “The disappointing clinical responses seen to date with pancreatic cancer vaccines are in line with those reported for vaccines used against other tumor histologies.(20) In contrast to these vaccination studies, Wobser and colleagues reported that a single patient vaccinated against survivin in the f”
Immune Checkpoint Targeting in Cancer Therapy: Towards Combination Strategies with Curative Potential (2015, background): “…were conducted with the best available science at the time and provided promising anecdotal evidence that induction of immune responses could elicit clinical benefit, they remained largely negative and generally failed to show objective clinical responses (see Rosenberg et al., 2004 for review).”